FDA Presents Guidance Agenda for 2016 How to Prepare Class II Devices for Compliance with The FDA’s UDI Mandate FDA Warning Letters 5 Indirect Costs of an FDA Warning Letter Process 4 Things the FDA Looks for in Quality Metrics Process Meaningful Use Program Suspended: What You Need to Know In the News 3 Things to Expect from the CDRH in 2016 and 2017 FDA Programs How a New FDA Program Helps Pharmaceuticals Implement Emerging Technology FDA Warning Letters 10 Key Elements of an FDA 483 Response Regulations FDA Group’s Larry Stevens Finds Major Issues With Sen. Cruz’s FDA Overhaul Proposal